The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry

Severe refractory asthma poses a substantial burden in terms of healthcare costs but relatively little is known about the factors which drive these costs. This study uses data from the British Thoracic Society Difficult Asthma Registry (n=596) to estimate direct healthcare treatment costs from an National Health Service perspective and examines factors that explain variations in costs. Annual mean treatment costs among severe refractory asthma patients were £2912 (SD £2212) to £4217 (SD £2449). Significant predictors of costs were FEV1% predicted, location of care, maintenance oral corticosteroid treatment and body mass index. Treating individuals with severe refractory asthma presents a substantial cost to the health service.

[1]  A. Gulsvik,et al.  The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults , 2012, International Archives of Allergy and Immunology.

[2]  Beverley Matthews,et al.  Estimating the financial cost of chronic kidney disease to the NHS in England , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  C. Bartlett,et al.  Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[4]  Teresa To,et al.  Global asthma prevalence in adults: findings from the cross-sectional world health survey , 2012, BMC Public Health.

[5]  L. Heaney,et al.  The Impact of Nonadherence to Inhaled Long-Acting β2-Adrenoceptor Agonist/Corticosteroid Combination Therapy on Healthcare Costs in Difficult-to-Control Asthma , 2012, Pharmaceutical Medicine.

[6]  L. Crofford,et al.  Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. , 2011, Clinical therapeutics.

[7]  D. Curran‐Everett,et al.  Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.

[8]  J. Shepherd,et al.  Omalizumab for the treatment of severe persistent allergic asthma. , 2009, Health Technology Assessment.

[9]  A. Cerulli,et al.  The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. , 2009, Respiratory medicine.

[10]  L. Lynd,et al.  Economic burden of asthma: a systematic review , 2009, BMC pulmonary medicine.

[11]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[12]  D. Quinton,et al.  Unit Costs of Health and Social Care 2004 , 2004 .

[13]  E. Yelin,et al.  A comprehensive study of the direct and indirect costs of adult asthma. , 2003, The Journal of allergy and clinical immunology.

[14]  M Britton,et al.  The burden of COPD in the U.K.: results from the Confronting COPD survey. , 2003, Respiratory medicine.

[15]  S. Spector,et al.  Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. , 2000, American journal of respiratory and critical care medicine.

[16]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[17]  Peter E. Kennedy.  Estimation with Correctly Interpreted Dummy Variables in Semilogarithmic Equations , 1981 .

[18]  R. Halvorsen,et al.  The Interpretation of Dummy Variables in Semilogarithmic Equations , 1980 .